Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls
Myrthe L Verburgh,Anders Boyd,Maarten F Schim van der Loeff,Margreet Bakker,Ferdinand W N M Wit,Marc van der Valk,Marloes Grobben,Lisa van Pul,Khadija Tejjani,Jacqueline van Rijswijk,Marit J van Gils,Neeltje A Kootstra,Lia van der Hoek,Peter Reiss,P Reiss,F W N M Wit,M van der Valk,A Boyd,M L Verburgh,I A J van der Wulp,M C Vanbellinghen,C J van Eeden,M F Schim van der Loeff,J C D Koole,L del Grande,I Agard,S Zaheri,M M J Hillebregt,Y M C Ruijs,D P Benschop,A el Berkaoui,A Boyd,F W N M Wit,N A Kootstra,A M Harskamp-Holwerda,I Maurer,M M Mangas Ruiz,B D N Boeser-Nunnink,O S Starozhitskaya,L van der Hoek,M Bakker,M J van Gils,L Dol,G Rongen,S E Geerlings,A Goorhuis,J W R Hovius,F J B Nellen,J M Prins,T van der Poll,M van der Valk,W J Wiersinga,M van Vugt,G de Bree,B A Lemkes,V Spoorenberg,F W N M Wit,J van Eden,F J J Pijnappel,A Weijsenfeld,S Smalhout,I J Hylkema - van den Bout,C Bruins,M E Spelbrink,P G Postema,P H L T Bisschop,E Dekker,N van der Velde,R Franssen,J M R Willemsen,L Vogt,P Portegies,G J Geurtsen,I Visser,A Schadé,P T Nieuwkerk,R P van Steenwijk,R E Jonkers,C B L M Majoie,M W A Caan,B J H van den Born,E S G Stroes,S van Oorspronk,
DOI: https://doi.org/10.1093/ofid/ofae380
2024-06-28
Open Forum Infectious Diseases
Abstract:Abstract Background Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGEhIV coronavirus disease 2019 substudy participants with well-controlled HIV on antiretroviral therapy and 280 comparable controls, who had received at least the primary vaccination series. Methods From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model. Results The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization. Conclusions People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration. NCT01466582
immunology,infectious diseases,microbiology